Introduction
Double-stranded RNA-dependent post-transcriptional gene silencing, also known as RNA interference (RNAi), is a phenomenon where double-stranded small interfering RNA (siRNA) complexes can target at specific genes. A 20-nt siRNA is long enough to induce RNAi [1 -3] . Expression of Bcl-2 has been observed in the majority of human cancer specimens and cell lines. Bcl-2 protein regulates the mitochondriamediated apoptosis pathway and various cell death stimuli, including chemotherapeutic agents. It also activates caspases by this pathway, thereby promoting apoptosis. A high level of expression of Bcl-2 is associated with resistance chemotherapeutic agents in a number of tumor types, so that a drug to reduce the levels of this protein would be expected to promote apoptosis and would therefore be considered as a promising therapeutic agent [4, 5] . At present, siRNA can be synthesized by chemical synthesis and in vitro transcription. The limitations of the two methods are the high cost and the low stability. Stable gene repression can be achieved in mammalian cells by using vectors to express small hairpin RNA (shRNA) structure with a U6 or H1 promoter under the direction of RNA polymerase III [6 -8] .
In our lab, we have identified an siRNA targeting at Bcl-2 mRNA by synthesis of transcription in vitro could effectively down-regulate Bcl-2 protein. A U6 promoter based on plasmid vector was used to express shRNA [9, 10] . In this study, we further investigated whether Bcl-2 shRNA could enhance cytarabine (Ara-C)-induced apoptosis in Raji cells, which might be helpful in developing new chemo-sensitization drugs for the treatment of lymphoma.
Materials and Methods

Reagents
The plasmid Pgenesil-1 was purchased from Genesil Biotechnology (Wuhan, China). Antibody against Bcl-2 (sc-509) was purchased from Santa Cruz (Santa Cruz, USA). RPMI 1640 and fetal calf serum were purchased from Gibco (Gaithersburg, USA). Ara-C was purchased from Suzhou Unite Pharmaceutical Corp. (Suzhou, China). In our lab, one effective siRNA sequence targeting against the region at 195-215 nt (GenBank accession No. M13995) of Bcl-2 mRNA has been identified by the synthesis of transcription in vitro. The Bcl-2 shRNA expression plasmid and a negative control hairpin RNA encoded a hairpin structure has been constructed and preserved in our lab [10] .
Cell culture and transfection with shRNA expression vector The Raji cell line was purchased from the Cell Bank of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). The cells were cultured in RPMI medium supplemented with 10% heat-inactivated fetal calf serum at 378C under 5% CO 2 in a humidified incubator. Raji cells in the exponential phase of growth were grown for 24 h, then transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, USA) according to the manufacturer's protocols. The ratio of Lipofectamine 2000 to plasmid was 1 ml/mg. In addition to medium control, cells were transfected with negative control shRNA. At 48 h of transfection, silencing of Bcl-2 gene was examined. At 4 h of transfection, Ara-C was added with final concentration of 10 mg/ml.
Assay of Bcl-2 mRNA by RT -PCR Total RNA was isolated by using Trizol total RNA isolation system (Invitrogen). One microgram of total RNA was reverse transcribed into first-strand cDNA by using cDNA synthesis kit (Promega, Madison, USA). PCR was carried out with a final volume of 50 ml for each reaction containing specific primers synthesized by Sangon (Shanghai, China) targeting at human Bcl-2 gene (forward, 5 0 -CGACGACTTCTCCCGCCGCTACCG C-3 0 ; reverse, 5 0 -CCGCATGCTGGGGCCGTACAG TTCC-3 0 ) and human glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH; forward, 5 0 -GTCA GTGG TGGACCTGACCT -3 0 ; reverse, 5 0 -TGAGGAGGGG AGATTCAGTG-3 0 ). GAPDH was used as an internal control. After 958C for 3 min, the experimental reaction consisting of 30 cycles of 958C for 30 s, 608C for 60 s, and 728C for 60 s, and the PCR products were analyzed by gel electrophoresis. The relative expression of Bcl-2 mRNA was quantitatively measured using densitometry analysis by gene expression analysis software.
Quantification of Bcl-2 protein using immunofluorescence by flow cytometry Transfected cells with shRNA and untreated Raji cells were collected by centrifugation (2000 g) for 5 min. The cells were washed twice and fixed in 4% formaldehyde (Sigma, St Louis, USA) for 30 min on ice, followed by permeabilization with 0.1% Triton X-100 in phosphatebuffered saline containing 1% albumin for 10 min at 48C. Cells were then washed in cold phosphate-buffered saline (PBS) before being added to 10 ml of mouse anti-human Bcl-2 monoclonal antibody (1:100) for 30 min at room temperature in the dark. After washing twice with PBS, 10 ml of Cy3-conjugated goat anti-mouse second antibody IgG was added. The secondary antibody (monoclonal antibody; Zhongshan Bio Corp., Zhongshan, China) was also used at a 1:100 dilution. After washing twice with PBS, the cells were examined by flow cytometry (BD, USA) and the percentage of cells with positive staining for Bcl-2 protein was determined.
Assay of cell viability
To determine whether Bcl-2 shRNA could enhance sensitization of Raji cells to Ara-C, the effects of Ara-C on Raji cells were estimated after Bcl-2 shRNA transfection by MTT assay [11] . The Raji cells were plated in 96-well plates at a density of 1 Â 10 5 cells/well in 200 ml RPMI 1640 and with 10% fetal calf serum. Four hours after transfection, Ara-C was used at 10 mg/ml. At 24, 48, and 72 h, 20 ml of MTT solution (5 mg/ml; Sigma) was added. After 4 h of incubation, the samples were centrifuged at 2000 g for 5 min. After removal of the supernatant, 200 ml of dimethyl sulfoxide (Sigma) was added to dissolve the crystals. Cell viability was calculated from the absorbance at 490 nm. The inhibition rates of cell growth were calculated according to the formula: inhibition rate (%) ¼ (1 2 mean absorbance of treated group/ mean absorbance of untreated group) Â 100%.
Assays of cell apoptosis
The transfected Raji cells were harvested after treated with Bcl-2 shRNA, followed by Ara-C, and fixed in methanol. Morphology was determined with Giemsa staining. The flow cytometry evaluation of the cell-cycle status and apoptosis was performed. Briefly, cells were centrifuged, washed in PBS, and fixed in 70% ethanol. The tubes containing the cell pellets were stored at 208C for at least 24 h. After that, the cells were centrifuged at 800 g for 15 min, and the supernatant was discarded to remove ethanol completely. The pellets were resuspended in 0.5 ml PBS and incubated with 20 mg/ml RNase A (Sigma) for 30 min at 378C, then stained with propidium iodide solution (20 mg/ml; Sigma) for 30 min. The DNA content was analyzed using a FACScan flow cytometry. Cells with DNA content below G 1 phase were regarded as apoptotic cells. The percentage of cells in the apoptotic sub-G 1 was analyzed by Multicycle software.
Statistical analysis
Results are shown as the mean + SD. Statistical comparisons were made by ANOVA. A value of P , 0.05 was considered to be statistically significant. All statistical analysis was carried out with SPSS 11.5.
Results
Inhibition of Bcl-2 mRNA expression using shRNA expression vectors The Bcl-2 and GAPDH genes are 318 and 400 bp, respectively. The gene expression ratio of Bcl-2/GAPDH was calculated as the level of Bcl-2 mRNA expression by the Bio-Rad Gel Doc1000 using Molecular Analyst software (Bio-Rad, Richmond, USA). RT-PCR experiments were run for three times and a representative result is shown in Fig. 1 . As shown in Fig. 1 , after 48 h of transient transfection, mRNA expression ratio (Bcl-2/ GAPDH) was 0.73 + 0.01 in the cells treated with Bcl-2 shRNA vector. In the cells treated with the negative control shRNA and pgenesil-1 empty vector, mRNA expression ratio (Bcl-2/GAPDH) was 0.98 + 0.03 and 0.98 + 0.08, respectively. Compared with the control, Bcl-2 mRNA expression was significantly reduced (P , 0.05), whereas the shRNA control and pgenesil-1 empty vector had no effect on the expression of Bcl-2 mRNA.
Effect of Bcl-2 shRNA on Bcl-2 protein levels To determine the effect of Bcl-2 shRNA on Bcl-2 protein levels, indirect immunofluorescence staining was performed. By flow cytometry assay, levels of Bcl-2 protein were (99.0 + 0.7)% in untransfected Raji cells; levels of Bcl-2 protein were (74.7 + 1.7)% at 48 h after transient transfection with Bcl-2 shRNA. Expression of Bcl-2 significantly decreased (P , 0.05) in the cells treated with Bcl-2 shRNA when compared with either negative control shRNA vector group (96.7 + 2.0)% or pgenesil-1 empty vector group (98.6 + 1.0)%. There was no difference in Bcl-2 levels among negative control shRNA group, pgenesil-1 empty vector, and untransfected cells (P . 0.05).
The effects of Ara-C on Raji cells transfected with Bcl-2 shRNA To investigate whether Bcl-2 shRNA has the potential to sensitize Raji cells to Ara-C, a combination treatment with Bcl-2 shRNA and Ara-C was applied. After 4 h of transfection, the cells were exposed to Ara-C. A summary of experiments measuring cell death at 24, 48, and 72 h is shown in Table 1 . Compared with treatments with either control shRNA plus Ara-C or Ara-C alone, the viability of the cells was significantly reduced by combining Bcl-2 shRNA and Ara-C in a timeindependent manner. There was no difference on the viability of the cells between control shRNA combined Ara-C and Ara-C alone.
Ara-C enhances apoptosis of cells transfected with Bcl-2 shRNA Two methods were used to assess apoptosis: Giemsa staining and FACS analysis. Raji cells presented characteristic of apoptosis (membrane blebbing, nuclear condensation, fragmentation, and formation of apoptotic bodies) (data not shown). Levels of apoptosis were (13.53 + 2.10)% at 48 h after transfection with Bcl-2 shRNA (Fig. 2) . However, a significant increase in apoptosis (P , 0.05) was observed after the combined treatment with both Bcl-2 shRNA and Ara-C (39.43 + 2.30)%, the difference in an apoptotic rate was significant, compared with Ara-C (17.10 + 0.20)% alone or control shRNA combined with Ara-C (17.32 + 1.10)%, respectively (P , 0.05). No significant difference in apoptosis occurred between those cells treated with control shRNA plus Ara-C or Ara-C alone (P . 0.05).
Discussion
Bcl-2 is a prominent member of the Bcl-2 family proteins that regulate the induction of apoptotic cell death by a wide variety of stimuli. Increased expression of Bcl-2 in tumor is considered as the major determinants of resistance to chemotherapeutic drugs and radiotherapy. Blocking of Bcl-2 expression and function may represent a relevant therapeutic strategy. Bcl-2 antisense oligonucleotides have succeeded in several preclinical and clinical studies. The currently ongoing Phase I and II clinical studies using antisense Bcl-2, known as G3139, aim at the treatment of patients with non-Hodgkin's lymphoma, melanoma, and prostate cancer [12] [13] [14] .
Lymphoma cell line Raji has been previously shown to produce large amounts of Bcl-2. Our previous studies showed that reduction in Bcl-2 expression by antisense oligonucleotides can induce apoptosis in Raji cells [15] . The data were shown as the mean + SD (n ¼ 3). *P , 0.05 vs. Ara-C þ negative shRNA group and Bcl-2shRNA group.
Recent investigations have shown the effectiveness of siRNA-mediated Bcl-2 inhibition in cancer cells [9, 10, 16, 17] . The siRNA against Bcl-2 could increase sensitivity to chemotherapeutical agents [18, 19] . However, whether shRNA against Bcl-2 could enhance Ara-C-induced apoptosis of lymphoma Raji cells remains uncertain. In this study, as expected, Raji cells transfected with Bcl-2 shRNA showed a greater decrease in cell proliferation and Bcl-2 expression as compared with control shRNA. Moreover, knockdown of Bcl-2 by shRNA enhanced Ara-C inhibiting growth of Raji cells. This synergistic pro-apoptotic effect also leads to a concurrent reduction in cell number. Both the apoptotic effect and cell number reduction in the combination treatment are significantly greater than that of either Ara-C or Bcl-2 shRNA treatment alone. There was no difference in the viability of the cells and the apoptotic rate between those treated with control shRNA plus Ara-C and Ara-C alone.
Our results indicated that down-regulation of Bcl-2 protein by Bcl-2 shRNA increased Ara-C-induced apoptosis in Raji cells. Bcl-2 shRNA may be useful for the treatment of tumor with overexpression of Bcl-2. As previously reported, the selective blockade of Bcl-2 could trigger the apoptosis and suppress the transduction of survival signals, thus leading to cancer cell growth inhibition, enhancing anti-tumor activity of drug [20] . It has been shown that down-regulation of Bcl-2 expression by siRNA increased the effect of doxorubicin in a canine mammary gland tumor cell line [18] . Another study showed that Bcl-2 siRNA-mediated gene silencing strengthened the sensitivity to the chemotherapeutic drugs 5-fluorouracil and 10-hydroxycamptothecin in human hepatoblastoma HepG2 cells [19] .
Our results showed that the combination of Bcl-2 shRNA and Ara-C produced a greater inhibitory effect on cell proliferation of Raji cells than the two treatments given separately, indicating that Bcl-2 knockdown caused a marked synergistic enhancement of Ara-C-induced apoptosis.
In our study, effectiveness of Bcl-2 gene silencing was low. We think that the lower inhibition rate in gene expression induced by Bcl-2 shRNA expression plasmid could be possibly explained by lower transfection efficiency of shRNA expression plasmid in suspension culture cells compared with that in siRNA delivery and(or) in adherent culture cells. Further investigations should be carried out in shRNA delivery with high transfection efficiency.
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